FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3169798496> ?p ?o ?g. }

• W3169798496 abstract "Background: As the COVID-19 pandemic unfolded, rapid case increase was observed in multiple cities in Iran. However, in the absence of seroprevalence surveys, the true infection rate remains unknown. In this population-based study we assessed the seroprevalence of SARS-CoV-2 antibodies in eighteen cities of Iran.Methods: We randomly selected and invited study participants from the general population (N = 3,547) and occupations with high risk of COVID-19 exposure, defined as high-risk population (e.g., supermarket employees) (N = 5,391), in eighteen cities of Iran. SARS-CoV-2 ELISA kits were used to detect antibody against COVID-19. Crude, population weight adjusted, and test performance adjusted seroprevalence rates were estimated.Findings: The population weight adjusted and test performance adjusted prevalence rates of antibody seropositivity in general population were 13·1% (95% CI 11·6-14·8%) and 18·5% (95% CI 16·1-21·3%), respectively. The population-weighted seroprevalence estimate implies that 3,290,633 (95% CI 2,907185-3,709,167) individuals, from the eighteen included cities in this study, were infected by end of April 2020.The overall prevalence rate was higher among individuals aged ≥ 60 years (32·0%, 95% CI 23·9-40·8%) and with comorbidity condition (23·7%, 95% CI 18·5-28·8%). The estimated seroprevalence of SARS-CoV-2 antibodies varied greatly by city and the highest population test-adjusted prevalence rates were in Rasht 78·1% (95% CI 58·3-98·3%) and Qom (66·5%, 95% CI 39·9-95·4%) cities. The test-adjusted prevalence did not differ between low and high-risk populations and was about 20.0%.Interpretations: The findings of this study imply that prevalence of seropositivity is likely much higher than the reported prevalence rates based on confirmed COVID-19 cases in Iran. Despite the high seroprevalence rates in a few cities, the low overall prevalence estimates indicate that a large proportion of population is still susceptible to the virus. The similar seroprevalence estimates between low and high-risk occupations might be an indicator of inadequate or low adherence to infection control measures among general population.Funding Statement: Iranian Ministry of Health and Medical Education COVID-19 Grant (number 99-1-97-47964).Declaration of Interests: None to disclose.Ethics Approval Statement: Ethics approval for this study was granted by Vice-Chancellor in Research Affairs-Tehran University of Medical Sciences (IR. TUMS.VCR.REC.1399.308)" @default.
• W3169798496 created "2021-06-22" @default.
• W3169798496 creator A5006562366 @default.
• W3169798496 creator A5011028101 @default.
• W3169798496 creator A5013106842 @default.
• W3169798496 creator A5013675371 @default.
• W3169798496 creator A5015958679 @default.
• W3169798496 creator A5016261721 @default.
• W3169798496 creator A5022138504 @default.
• W3169798496 creator A5024561441 @default.
• W3169798496 creator A5025877875 @default.
• W3169798496 creator A5026340422 @default.
• W3169798496 creator A5027832334 @default.
• W3169798496 creator A5029026713 @default.
• W3169798496 creator A5033544451 @default.
• W3169798496 creator A5034140174 @default.
• W3169798496 creator A5041008202 @default.
• W3169798496 creator A5042463292 @default.
• W3169798496 creator A5045429297 @default.
• W3169798496 creator A5047308140 @default.
• W3169798496 creator A5047799517 @default.
• W3169798496 creator A5049018082 @default.
• W3169798496 creator A5049355998 @default.
• W3169798496 creator A5051197496 @default.
• W3169798496 creator A5051406372 @default.
• W3169798496 creator A5052061730 @default.
• W3169798496 creator A5052366413 @default.
• W3169798496 creator A5054932159 @default.
• W3169798496 creator A5060946051 @default.
• W3169798496 creator A5066699251 @default.
• W3169798496 creator A5066815614 @default.
• W3169798496 creator A5072314821 @default.
• W3169798496 creator A5073442286 @default.
• W3169798496 creator A5075247147 @default.
• W3169798496 creator A5077058925 @default.
• W3169798496 creator A5077880208 @default.
• W3169798496 creator A5078563387 @default.
• W3169798496 creator A5081689734 @default.
• W3169798496 creator A5083834017 @default.
• W3169798496 creator A5086567711 @default.
• W3169798496 creator A5086697726 @default.
• W3169798496 creator A5090424377 @default.
• W3169798496 creator A5091012451 @default.
• W3169798496 date "2020-01-01" @default.
• W3169798496 modified "2023-09-26" @default.
• W3169798496 title "COVID-19 Antibody Seroprevalence Among General Population and High-Risk Occupational Groups in Eighteen Cities of Iran" @default.
• W3169798496 doi "https://doi.org/10.2139/ssrn.3647115" @default.
• W3169798496 hasPublicationYear "2020" @default.
• W3169798496 type Work @default.
• W3169798496 sameAs 3169798496 @default.
• W3169798496 citedByCount "0" @default.
• W3169798496 crossrefType "journal-article" @default.
• W3169798496 hasAuthorship W3169798496A5006562366 @default.
• W3169798496 hasAuthorship W3169798496A5011028101 @default.
• W3169798496 hasAuthorship W3169798496A5013106842 @default.
• W3169798496 hasAuthorship W3169798496A5013675371 @default.
• W3169798496 hasAuthorship W3169798496A5015958679 @default.
• W3169798496 hasAuthorship W3169798496A5016261721 @default.
• W3169798496 hasAuthorship W3169798496A5022138504 @default.
• W3169798496 hasAuthorship W3169798496A5024561441 @default.
• W3169798496 hasAuthorship W3169798496A5025877875 @default.
• W3169798496 hasAuthorship W3169798496A5026340422 @default.
• W3169798496 hasAuthorship W3169798496A5027832334 @default.
• W3169798496 hasAuthorship W3169798496A5029026713 @default.
• W3169798496 hasAuthorship W3169798496A5033544451 @default.
• W3169798496 hasAuthorship W3169798496A5034140174 @default.
• W3169798496 hasAuthorship W3169798496A5041008202 @default.
• W3169798496 hasAuthorship W3169798496A5042463292 @default.
• W3169798496 hasAuthorship W3169798496A5045429297 @default.
• W3169798496 hasAuthorship W3169798496A5047308140 @default.
• W3169798496 hasAuthorship W3169798496A5047799517 @default.
• W3169798496 hasAuthorship W3169798496A5049018082 @default.
• W3169798496 hasAuthorship W3169798496A5049355998 @default.
• W3169798496 hasAuthorship W3169798496A5051197496 @default.
• W3169798496 hasAuthorship W3169798496A5051406372 @default.
• W3169798496 hasAuthorship W3169798496A5052061730 @default.
• W3169798496 hasAuthorship W3169798496A5052366413 @default.
• W3169798496 hasAuthorship W3169798496A5054932159 @default.
• W3169798496 hasAuthorship W3169798496A5060946051 @default.
• W3169798496 hasAuthorship W3169798496A5066699251 @default.
• W3169798496 hasAuthorship W3169798496A5066815614 @default.
• W3169798496 hasAuthorship W3169798496A5072314821 @default.
• W3169798496 hasAuthorship W3169798496A5073442286 @default.
• W3169798496 hasAuthorship W3169798496A5075247147 @default.
• W3169798496 hasAuthorship W3169798496A5077058925 @default.
• W3169798496 hasAuthorship W3169798496A5077880208 @default.
• W3169798496 hasAuthorship W3169798496A5078563387 @default.
• W3169798496 hasAuthorship W3169798496A5081689734 @default.
• W3169798496 hasAuthorship W3169798496A5083834017 @default.
• W3169798496 hasAuthorship W3169798496A5086567711 @default.
• W3169798496 hasAuthorship W3169798496A5086697726 @default.
• W3169798496 hasAuthorship W3169798496A5090424377 @default.
• W3169798496 hasAuthorship W3169798496A5091012451 @default.
• W3169798496 hasConcept C126322002 @default.
• W3169798496 hasConcept C159047783 @default.
• W3169798496 hasConcept C159654299 @default.
• W3169798496 hasConcept C162324750 @default.
• W3169798496 hasConcept C203014093 @default.
• W3169798496 hasConcept C205649164 @default.
• W3169798496 hasConcept C2778494684 @default.

• next